Skip to main content

Advertisement

SpringerLink
Log in

Estrogen receptor: is it predictive for response to cytotoxic as well as hormonal therapy?

  • Invited Commentary
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Bonetti M, Gelber RD (2000) A graphical method to assess treatment—covariate interactions using the Cox model on subsets of the data. Stat Med 19:2595–2609. doi:10.1002/1097-0258(20001015)19:19<2595::AID-SIM562>3.0.CO;2-M

    Article  PubMed  CAS  Google Scholar 

  2. Bonetti M, Gelber RD (2004) Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics 5:465–481. doi:10.1093/biostatistics/kxh002

    Article  PubMed  Google Scholar 

  3. Regan MM, Gelber RD, For the International Breast Cancer Study Group (2006) Predicting response to systemic treatments; learning from the past to plan for the future. Breast 14:582–593. doi:10.1016/j.breast.2005.08.021

    Article  Google Scholar 

  4. Regan MM, Gelber RD (2007) Using clinical trial data to tailor adjuvant treatments for individual patients. Breast 16:98–104. doi:10.1016/j.breast.2007.07.016

    Article  Google Scholar 

  5. Berry DA, Cirrincione C, Henderson IC et al (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658–1667. doi:10.1001/jama.295.14.1658

    Article  PubMed  CAS  Google Scholar 

  6. Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976–983. doi:10.1200/JCO.2003.02.063

    Article  PubMed  CAS  Google Scholar 

  7. Citron M, Berry D, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/cancer and leukemia group B Trial 9741. J Clin Oncol 21:1–9. doi:10.1200/JCO.2003.09.081

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sunnybrook Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

    Kathleen I. Pritchard

Authors
  1. Kathleen I. Pritchard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathleen I. Pritchard.

Additional information

An invited commentary on “Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century” by Pagani et al. (doi:10.1007/s10549-008-0282-0).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pritchard, K.I. Estrogen receptor: is it predictive for response to cytotoxic as well as hormonal therapy?. Breast Cancer Res Treat 127, 587–588 (2011). https://doi.org/10.1007/s10549-009-0325-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-009-0325-1

Keywords

Search

Navigation